ADMA
NASDAQADMA Biologics Inc
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks36+67%
2026-03-012026-08-23
Mix1190d
- Insider3(27%)
- SEC Filings3(27%)
- Earnings2(18%)
- Other2(18%)
- Analyst1(9%)
Latest news
25 items- PRBerger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)PHILADELPHIA, Aug. 17, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV. Shareholders of ADMA may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Caitlin Adorni at cadorni@bergermontague.com or (267)
- SECSEC Form SCHEDULE 13G filed by ADMA Biologics IncSCHEDULE 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)
- SECSEC Form 10-Q filed by ADMA Biologics Inc10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- SECADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- PRADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue 2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year 2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year 2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year 2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Year-over-Year Strong Balance Sheet and Financial Flexibility Support Continued Execution ACAAI Abstract Submitted Highlighting Significant Real-World Health Outcomes and Healthcare Resource Util
- PRADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report second quarter 2026 financial results on August 5, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to
- INSIDERCOO and SVP, Compliance Kestenberg-Messina Kaitlin M. covered exercise/tax liability with 3,177 shares, decreasing direct ownership by 0.71% to 443,061 units (SEC Form 4) (withholding obligation)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERCFO and Treasurer Kohler Terry was granted 85,130 shares, increasing direct ownership by 147% to 143,149 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- ANALYSTRaymond James resumed coverage on ADMA Biologics with a new price targetRaymond James resumed coverage of ADMA Biologics with a rating of Outperform and set a new price target of $21.00
- SECADMA Biologics Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- INSIDERDirector Grossman Jerrold B bought $50,624 worth of shares (6,400 units at $7.91), increasing direct ownership by 1% to 520,284 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERDirector Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 2% to 513,884 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- INSIDERDirector Grossman Jerrold B bought $100,125 worth of shares (12,500 units at $8.01), increasing direct ownership by 3% to 501,384 units (SEC Form 4)4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- SECSEC Form 10-Q filed by ADMA Biologics Inc10-Q - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- SECADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- PRADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income(1) of $40.7 Million, 22% Year-Over-Year Growth 1Q 2026 Adjusted EBITDA(2) of $59.7 Million, Representing 24% Year-Over-Year Growth 1Q 2026 Cash from Operations of $58 Million Highlights Strong Cash Generation Strong Balance Sheet and Financial Flexibility Support Continued Execution Reiterates Confidence in ASCENIV Growth Outlook Driven by Durable Demand Fundamentals Updates FY 2026 Outlook and Withdraws Long-Term Guidance to Reflect Evolving U.S. Plasma Products and IG Market Competitive Dynamics RAMSEY, N.J. and
- SECADMA Biologics Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- PRADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and OlderRAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the U.S. Food and Drug Administration ("FDA") has approved the Company's supplemental Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for ASCENIV™. The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment. Additionally, the approval provides for a revision of ASCENIV's prescribing information t
- PRADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report first quarter 2026 financial results on May 6, 2026, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and uniq
- ANALYSTCanaccord Genuity initiated coverage on ADMA Biologics with a new price targetCanaccord Genuity initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $21.00
- SECSEC Form DEFA14A filed by ADMA Biologics IncDEFA14A - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- SECSEC Form DEF 14A filed by ADMA Biologics IncDEF 14A - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- INSIDERSEC Form 4 filed by Kestenberg-Messina Kaitlin M.4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)
- SECADMA Biologics Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)
- PRADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper ResearchShort seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines Highlights that Demand for – and Utilization of – ASCENIV Has Grown Steadily Over Past Two Years and is at Record High Details that Stocking Levels Maintained by ADMA's Distributors Align with Industry Standards and Reflect the Long Production Cycle for ASCENIV RAMSEY, N.J. and BOCA RATON, Fla., March 27, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company ded
ADMA FAQ
6 questionsWhat does ADMA Biologics Inc do?
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including...Where does ADMA stock trade?
ADMA Biologics Inc (ADMA) is listed on NASDAQ.What sector and industry is ADMA in?
ADMA Biologics Inc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about ADMA?
ADMA Biologics Inc has had 8 recent analyst actions on file. The most recent action was from Raymond James: Outperform with a $2100.00 price target on 2026-06-10. Recent price targets range from $450.00 to $2100.00.What companies are similar to ADMA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ADMA side-by-side with any of them on Quantisnow.How can I track ADMA on Quantisnow?
Quantisnow aggregates ADMA Biologics Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADMA to receive live email and push alerts on every new disclosure.